AbCellera is a technology company that is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner.

Technology Overview

AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.


"In recent years we have made a series of investments into the next generation of therapeutic antibodies. We are seeing a wave of innovation in the antibody space that is allowing us to add novel functionalities to these molecules. Our partnership with AbCellera will further enable our portfolio companies to pursue these important biologic medicines.”
Markus Enzelberger, Ph.D., Versant partner
"This collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer. We are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology."
Patrick Mayes, Ph.D., Vice President, BioTherapeutics at Incyte
“I am pleased to see AbCellera participating in our government’s effort to reverse a four-decade decline in Canada’s domestic capacity. This is an important step toward improving Canada’s pandemic preparedness, and a driver for our economic recovery.”
François-Philippe Champagne, minister of innovation, science and industry, quote from Endpoints
"We continue to be impressed with the speed of discovery, the quality, and the diversity of the antibodies AbCellera delivers. Through this agreement, we have secured expanded access to an industry-leading technology to accelerate the discovery of antibody-based therapies for patients with neurological diseases."
Alexander Schuth, COO